Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/96000
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection
Author: Dore, G.
Lawitz, E.
Hézode, C.
Shafran, S.
Ramji, A.
Tatum, H.
Taliani, G.
Tran, A.
Brunetto, M.
Zaltron, S.
Strasser, S.
Weis, N.
Ghesquiere, W.
Lee, S.
Larrey, D.
Pol, S.
Harley, H.
George, J.
Fung, S.
de Lédinghen, V.
et al.
Citation: Gastroenterology, 2015; 148(2):355-366
Publisher: Elsevier
Issue Date: 2015
ISSN: 0016-5085
1528-0012
Statement of
Responsibility: 
Gregory J. Dore ... Hugh Harley ... et al.
Abstract: BACKGROUND & AIMS: Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%-80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and shortens therapy. METHODS: Patients with HCV genotype 2 or 3 infection (n = 151), enrolled at research centers in North America, Europe, or Australia, were assigned randomly to groups given 12 or 16 weeks of daclatasvir (60 mg once daily), or 24 weeks of placebo, each combined with peginterferon alfa-2a and ribavirin. Treatment was extended to 24 weeks for recipients of daclatasvir who did not meet the criteria for early virologic response. The primary end point was SVR at 24 weeks after treatment (SVR24). RESULTS: Baseline characteristics were similar among patients within each HCV genotype group. However, the 80 patients with HCV genotype 3, compared with the 71 patients with HCV genotype 2, were younger (mean age, 45 vs 53 y, respectively), and a larger proportion had cirrhosis (23% vs 1%, respectively). Among patients with HCV genotype 2 infection, an SVR24 was achieved by 83%, 83%, and 63% of those in the daclatasvir 12-week group, the daclatasvir 16-week group, or the placebo group, respectively; among patients with HCV genotype 3 infection, an SVR24 was achieved by 69%, 67%, and 59% of patients in these groups, respectively. Differences between genotypes largely were attributable to the higher frequency of post-treatment relapse among patients infected with HCV genotype 3. In both daclatasvir arms for both HCV genotypes, the lower bound of the 80% confidence interval of the difference in SVR24 rates between the daclatasvir and placebo arms was above -20%, establishing noninferiority. Safety findings were similar among groups, and were typical of those expected from peginterferon alfa and ribavirin therapy. CONCLUSIONS: Twelve or 16 weeks of treatment with daclatasvir, in combination with peginterferon alfa-2a and ribavirin, is a well tolerated and effective therapy for patients with HCV genotype 2 or 3 infections. Daclatasvir-containing regimens could reduce the duration of therapy for these patients. Clinicaltrials.gov number: NCT01257204.
Keywords: Antiviral; Combination Therapy; NS5A Replication Complex Inhibitor; DAA
Description: Has a Supplementary Figure 1 on page 366.e1
Rights: © 2015 AGA Institute
RMID: 0030029419
DOI: 10.1053/j.gastro.2014.10.007
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.